Affimed (NASDAQ:AFMD) Stock Price Crosses Below Fifty Day Moving Average – Should You Sell?

Shares of Affimed (NASDAQ:AFMD) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.42 and traded as low as $1.31. Affimed shares last traded at $1.32, with a volume of 278,795 shares.

Analysts Set New Price Targets

Several analysts have weighed in on AFMD shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Affimed in a research note on Tuesday, December 10th. Wells Fargo & Company reduced their price objective on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, December 12th. Finally, Stifel Nicolaus lowered their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Friday, November 15th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Affimed presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.50.

Affimed Stock Performance

The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. The stock has a 50 day moving average price of $2.38 and a 200 day moving average price of $3.57.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AFMD. Choreo LLC bought a new stake in shares of Affimed during the 2nd quarter worth $54,000. Point72 Asset Management L.P. boosted its position in shares of Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares during the period. Intellectus Partners LLC increased its stake in Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 10,250 shares in the last quarter. Jane Street Group LLC acquired a new stake in Affimed during the 3rd quarter worth about $44,000. Finally, FMR LLC raised its holdings in Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 4,086 shares during the period. Institutional investors and hedge funds own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.